2025-05-17 - Analysis Report
Okay, here's the analysis of Teva Pharmaceutical Industries Ltd ADR (TEVA), presented in a report format with numerical data first, followed by analysis:

**Report: Teva Pharmaceutical Industries Ltd ADR (TEVA) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TEVA
*   **Company Description:** Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines.
*   **TEVA Cumulative Return:** 56.68%
*   **VOO (S&P 500) Cumulative Return:** 84.12%
*   **Relative Performance Spread:**
    *   Max: 21.9
    *   Min: -122.3
    *   Current: -27.4
    *   Relative Spread Position: 65.8

**Analysis:** TEVA has significantly underperformed the S&P 500 over the analyzed period. The current relative spread position of 65.8 indicates that TEVA is performing better than its historical worst, but still lagging behind the S&P 500.

**Alpha, Beta Analysis:**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |  -44   |  58.4 |   -73   |   -0   |     21.9 |
| 2016-2018  |  -41   |  70.4 |   -59   |   -0.1 |     17.8 |
| 2017-2019  |  -16   |  70.4 |   -45   |   -0.2 |     11.3 |
| 2018-2020  |    0   |  70.4 |   -25   |   -0.2 |     11.2 |
| 2019-2021  |  -22   |  58.3 |   -76   |   -0.2 |      9.3 |
| 2020-2022  |   27   |  74.8 |    20   |   -0.2 |     10.5 |
| 2021-2023  |   38   |  74.8 |    21   |   -0.8 |     12.1 |
| 2022-2024  |  122   |  74.8 |   106   |   -0.7 |     25.5 |
| 2023-2025  |   67   |  76   |    35   |    0.1 |     19.6 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows highly variable performance across different periods, with significant losses in earlier periods and substantial gains more recently.
*   **MDD:** The Maximum Drawdown (MDD) indicates substantial risk and volatility, consistently exceeding 50% across all periods, highlighting significant potential losses.
*   **Alpha:** Alpha values are largely negative, indicating underperformance relative to the market, especially in earlier years. Recent years show positive Alpha, suggesting improved performance relative to the benchmark.
*   **Beta:** Beta values are generally negative, suggesting an inverse correlation or reduced sensitivity to market movements, which could be a mix of strategic repositioning or inherent risk mitigation.
*   **Cap(B):** The market capitalization figures show some fluctuations over the years, reflecting the company's changing valuation and investor sentiment.

**2. Recent Price Action**

*   **Current Price:** 16.94
*   **Previous Close:** 16.87
*   **Price Change:** 0.41
*   **5-Day Moving Average:** 17.23
*   **20-Day Moving Average:** 16.02
*   **60-Day Moving Average:** 15.59

**Analysis:** The current price is above both the 20-day and 60-day moving averages, which is a bullish signal. However, it's slightly below the 5-day moving average, suggesting a possible short-term pullback. The minor positive change from the previous close doesn't indicate any significant volatility event.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3475 (Low Risk)
*   **RSI:** 63.60
*   **PPO:** 0.5777
*   **20-Day Relative Spread Change:** -6.4 (Short-term decrease)
*   **Expected Return:** -37.1%

**Analysis:**

*   The MRI suggests a low-risk environment for the stock.
*   The RSI is approaching overbought territory (above 70), indicating the stock may be due for a correction.
*   The PPO is positive, indicating an uptrend.
*   The negative change in the 20-day relative spread suggests recent underperformance compared to the S&P 500.
*   The negative expected return suggests potential underperformance compared to the S&P 500 over the long term (2+ years) if investing at the current price.

**4. Recent News & Significant Events**

*   **May 16, 2025:** Major business developments, regulatory changes, or market events.
*   **May 17, 2025:** Analyst discussions regarding recent performance and outlook.
*   **May 13, 2025:** Notable stock volatility.
*   **May 15, 2025:** Market expert analysis of risks and opportunities.

**Analysis:** Recent news suggests potential volatility and significant events impacting the stock. Investors should monitor news and announcements closely.

**5. Recent Earnings Analysis**

| 날짜       |   EPS | 매출     |
|:-----------|------:|:---------|
| 2025-05-07 |  0.19 | 3.89 B$  |
| 2024-11-06 | -0.39 | 4.33 B$  |
| 2024-07-31 | -0.75 | 4.16 B$  |
| 2024-05-08 | -0.12 | 3.82 B$  |
| 2025-05-07 | -0.12 | 3.82 B$  |

**Analysis:** The most recent earnings per share (EPS) is positive (0.19), but the trend over the last few quarters has been inconsistent, with previous quarters showing negative EPS. Revenue has also fluctuated.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue  | Profit Margin   |
|:-----------|:---------|:----------------|
| 2025-03-31 | $3.89B   | 48.24%          |
| 2024-12-31 | $4.23B   | 50.15%          |
| 2024-09-30 | $4.33B   | 49.60%          |
| 2024-06-30 | $4.16B   | 48.61%          |
| 2024-03-31 | $3.82B   | 46.37%          |

Capital and Profitability:

| Quarter    | Equity   | ROE     |
|:-----------|:---------|:--------|
| 2025-03-31 | $6.26B   | 3.42%   |
| 2024-12-31 | $5.37B   | -4.04%  |
| 2024-09-30 | $6.07B   | -7.21%  |
| 2024-06-30 | $6.36B   | -13.30% |
| 2024-03-31 | $7.28B   | -1.91%  |

**Analysis:**

*   **Revenue:** Revenue has been fluctuating, with some quarters showing better performance than others.
*   **Profit Margin:** The profit margin has remained relatively stable.
*   **Equity:** Equity has decreased over the past year.
*   **ROE:** The Return on Equity (ROE) has been inconsistent, with some quarters showing positive returns and others showing losses.

**7. Overall Analysis**

Teva Pharmaceutical Industries Ltd ADR (TEVA) presents a mixed picture. While recent price action shows some bullish signs (price above 20-day and 60-day moving averages), the RSI suggests it may be approaching overbought territory. The company has significantly underperformed the S&P 500 over the analyzed period. The recent earnings show mixed results, with the latest quarter showing positive EPS but with inconsistency in the past. Recent news indicates potential volatility and significant events impacting the stock. Long-term expected returns are negative. Overall, TEVA appears to be a high-risk, potentially high-reward investment that requires careful monitoring.
